.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Teva
Cipla
Baxter
QuintilesIMS
Novartis
Express Scripts
Dow
Harvard Business School
US Army

Generated: September 24, 2017

DrugPatentWatch Database Preview

Selegiline - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for selegiline and what is the scope of selegiline patent protection?

Selegiline
is the generic ingredient in four branded drugs marketed by Somerset, Boscogen, Apotex, G And W Labs Inc, Chartwell Molecules, Lannett Holdings Inc, Dava Pharms Inc, Mylan, Apotex Inc, Siegfried, and Valeant Pharm Intl, and is included in sixteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Selegiline has three patent family members in two countries.

There are seventeen drug master file entries for selegiline. One supplier is listed for this compound.

Summary for Generic Name: selegiline

Tradenames:4
Patents:3
Applicants:11
NDAs:16
Drug Master File Entries: see list17
Suppliers / Packagers: see list1
Bulk Api Vendors: see list15
Clinical Trials: see list33
Patent Applications: see list5,490
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:selegiline at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boscogen
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074912-001Apr 30, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-003Feb 27, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Dava Pharms Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
CAPSULE;ORAL075352-001Nov 30, 1998ABRXNoNo► Subscribe► Subscribe► Subscribe
Chartwell Molecules
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074641-001Aug 2, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-001Feb 27, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-002Feb 27, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Somerset
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL019334-001Jun 5, 1989DISCNYesNo► Subscribe► Subscribe► Subscribe
Apotex Inc
SELEGILINE HYDROCHLORIDE
selegiline hydrochloride
TABLET;ORAL074871-001Jun 6, 1997ABRXNoYes► Subscribe► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-001Feb 27, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Valeant Pharm Intl
ZELAPAR
selegiline hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021479-001Jun 14, 2006RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: selegiline

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-001Feb 27, 2006► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-002Feb 27, 2006► Subscribe► Subscribe
Somerset
EMSAM
selegiline
FILM, EXTENDED RELEASE;TRANSDERMAL021336-003Feb 27, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: selegiline

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,093Adhesive mixture for transdermal delivery of highly plasticizing drugs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: selegiline

Country Document Number Estimated Expiration
European Patent Office1561461► Subscribe
JapanH1160475► Subscribe
European Patent Office0887075► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Baxter
Argus Health
Cantor Fitzgerald
Mallinckrodt
Fuji
Medtronic
QuintilesIMS
Express Scripts
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot